Taiwan’s MegaPro Biomedical Co (巨生生醫) and China Chemical & Pharmaceutical Co (CCPC, 中國化學製藥) yesterday announced that they have set up a joint venture with China’s Wellbridge Biotech Ltd (蘇州瑋琪) focusing on the development of drugs in inhalation dosage forms.
MegaPro said it would invest about US$600,000 for a 30 percent stake in the joint venture — Trium Therapeutics Co — while CCPC and Wellbridge would hold 40 percent and 30 percent respectively.
Trium’s chairman and general manager are to be appointed by CCPC and MegaPro respectively, it said.
Photo: Grace Hung, Taipei Times
Trium’s main research goal is to meet pharmaceutical companies’ demand for non-invasive routes of drug administration, such as via the nasal cavity, to improve patients’ comfort and drugs’ bioavailability, MegaPro said.
MegaPro would utilize its expertise in improving drug delivery technology and develop new dosage forms on its nano-platform technology, it said.
MegaPro would also be responsible for conducting animal tests and human trials, it added.
CCPC, which operates Good Manufacturing Practice-certified pharmaceutical plants, as well as sales channels at home and abroad, would be responsible for mass production and marketing, while Wellbridge, which specializes in medical nebulizers, would provide technical information for the development of inhalation dosage forms and supply nebulizer equipment, the companies said.
“Oral dosage forms have been well-developed and widely used by generic drug manufacturing pharmaceutical companies. How to expand special treatment pathways has become the next phase of development in the pharmaceutical industry,” CCPC general manager Wu Zhi-yong (吳志庸) said in a statement.
Reports by Data Bridge Market Research Private Ltd, a professional research company, show that the global market for inhalers is expected to reach US$42.1 billion in 2027, with a compound annual growth rate of 5.87 percent from this year to 2027, MegaPro said.
As patients inhale the drug, its main components can be quickly absorbed by the lungs and dense blood capillaries, it said.
Trium has completed the screening of drug candidates and the preliminary animal tests, and would carry out stability tests and more animal tests, the companies said.
Spun off in 2014 from the Industrial Technology Research Institute, MegaPro focuses on developing niche nano-medicines and holds two proprietary nanotechnology platforms, with three product pipelines treating iron deficiency anemia and hepatocellular carcinoma.
MegaPro reported zero revenue for the first half of this year, while CCPC’s revenue was flat from a year earlier at NT$4.03 billion (US$135.2 million), companies’ data showed.
Hong Kong authorities ramped up sales of the local dollar as the greenback’s slide threatened the foreign-exchange peg. The Hong Kong Monetary Authority (HKMA) sold a record HK$60.5 billion (US$7.8 billion) of the city’s currency, according to an alert sent on its Bloomberg page yesterday in Asia, after it tested the upper end of its trading band. That added to the HK$56.1 billion of sales versus the greenback since Friday. The rapid intervention signals efforts from the city’s authorities to limit the local currency’s moves within its HK$7.75 to HK$7.85 per US dollar trading band. Heavy sales of the local dollar by
Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) revenue jumped 48 percent last month, underscoring how electronics firms scrambled to acquire essential components before global tariffs took effect. The main chipmaker for Apple Inc and Nvidia Corp reported monthly sales of NT$349.6 billion (US$11.6 billion). That compares with the average analysts’ estimate for a 38 percent rise in second-quarter revenue. US President Donald Trump’s trade war is prompting economists to retool GDP forecasts worldwide, casting doubt over the outlook for everything from iPhone demand to computing and datacenter construction. However, TSMC — a barometer for global tech spending given its central role in the
The Financial Supervisory Commission (FSC) yesterday met with some of the nation’s largest insurance companies as a skyrocketing New Taiwan dollar piles pressure on their hundreds of billions of dollars in US bond investments. The commission has asked some life insurance firms, among the biggest Asian holders of US debt, to discuss how the rapidly strengthening NT dollar has impacted their operations, people familiar with the matter said. The meeting took place as the NT dollar jumped as much as 5 percent yesterday, its biggest intraday gain in more than three decades. The local currency surged as exporters rushed to
PRESSURE EXPECTED: The appreciation of the NT dollar reflected expectations that Washington would press Taiwan to boost its currency against the US dollar, dealers said Taiwan’s export-oriented semiconductor and auto part manufacturers are expecting their margins to be affected by large foreign exchange losses as the New Taiwan dollar continued to appreciate sharply against the US dollar yesterday. Among major semiconductor manufacturers, ASE Technology Holding Co (日月光), the world’s largest integrated circuit (IC) packaging and testing services provider, said that whenever the NT dollar rises NT$1 against the greenback, its gross margin is cut by about 1.5 percent. The NT dollar traded as strong as NT$29.59 per US dollar before trimming gains to close NT$0.919, or 2.96 percent, higher at NT$30.145 yesterday in Taipei trading
RSS